Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) Transcript
Well, good morning and welcome, everyone, to the next session at the Raymond James Human Health Innovation Conference. I am Steve Seedhouse. It really is a pleasure for me to welcome the next participating company at our conference, InflaRx. InflaRx is a biotech company developing an anti-C5a antibody, vilobelimab or IFX-1, formally for inflammatory immune disorders. And I'm joined by, of course, CEO, Niels Riedemann; and Chief Strategy Officer, Jordan Zwick; and really looking forward to our virtual fireside chat.
So I would just also mention that listeners are invited to submit questions if you'd like via OpenExchange or you can email me directly.
Questions & Answers
But with that, would like to just hop right into it. And Niels, I wanted to start with your Hidradenitis Suppurativa program. Talk about basically the latest update, which was essentially that the FDA remains committed to HiSCR endpoint, which is what you used in your Phase II
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
